AU7622698A - Use of indolinone compounds as modulators of protein kinases - Google Patents

Use of indolinone compounds as modulators of protein kinases

Info

Publication number
AU7622698A
AU7622698A AU76226/98A AU7622698A AU7622698A AU 7622698 A AU7622698 A AU 7622698A AU 76226/98 A AU76226/98 A AU 76226/98A AU 7622698 A AU7622698 A AU 7622698A AU 7622698 A AU7622698 A AU 7622698A
Authority
AU
Australia
Prior art keywords
modulators
protein kinases
indolinone compounds
indolinone
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76226/98A
Inventor
Gerald Mcmahon
Li Sun
Peng Cho Tang
Ngoc My Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU7622698A publication Critical patent/AU7622698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
AU76226/98A 1996-12-05 1997-12-02 Use of indolinone compounds as modulators of protein kinases Abandoned AU7622698A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3158796P 1996-12-05 1996-12-05
US60/031587 1996-12-05
US4571697P 1997-05-06 1997-05-06
US60/045716 1997-05-06
PCT/US1997/022210 WO1998024432A2 (en) 1996-12-05 1997-12-02 Use of indolinone compounds as modulators of protein kinases

Publications (1)

Publication Number Publication Date
AU7622698A true AU7622698A (en) 1998-06-29

Family

ID=26707416

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76226/98A Abandoned AU7622698A (en) 1996-12-05 1997-12-02 Use of indolinone compounds as modulators of protein kinases

Country Status (2)

Country Link
AU (1) AU7622698A (en)
WO (1) WO1998024432A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756378B2 (en) * 1998-01-22 2003-01-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of inhibitors for the treatment of disorders related to RTK hyperfunction, especially cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EA005032B1 (en) 1998-05-29 2004-10-28 Сьюджен, Инк. Pyrrole substituted 2-indolinone (variants), pharmaceutical composition (variants), method for modulation of catalytic activity method for treating and preventing a protein kinase related disorders in an organism
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
KR100649925B1 (en) 1998-12-17 2007-02-28 에프. 호프만-라 로슈 아게 4-alkenyl and alkynyl oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
BR9916324A (en) 1998-12-17 2001-10-02 Hoffmann La Roche 4,5-pyrazinoxindoles as protein kinase inhibitors
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
CA2368041A1 (en) * 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2001094312A2 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
DE10237423A1 (en) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05010765A (en) 2003-04-10 2005-12-12 Hoffmann La Roche Pyrimido compounds.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
WO1993012786A1 (en) * 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756378B2 (en) * 1998-01-22 2003-01-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of inhibitors for the treatment of disorders related to RTK hyperfunction, especially cancer

Also Published As

Publication number Publication date
WO1998024432A2 (en) 1998-06-11
WO1998024432A3 (en) 1998-08-13

Similar Documents

Publication Publication Date Title
AU7622698A (en) Use of indolinone compounds as modulators of protein kinases
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU1529997A (en) Substituted histidine inhibitors of protein farnesyltransferase
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
AU8030598A (en) Indole compounds as cox-2 inhibitors
AU7398194A (en) Oligonucleotide modulation of protein kinase c
AU4265496A (en) Perhydroisoindole derivatives as antagonists of substance p
AU2805897A (en) Inhibitors of protein farnesyltransferase
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
AU2362595A (en) Novel megakaryocytic protein tyrosine kinases
HUP0100302A3 (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
AU690163B2 (en) Antimigraine derivatives of indolylcycloalkanylamines
AU1866499A (en) Compounds and methods for modulating synaptic stability
AU2144799A (en) The preparation of novel gels for the purification of non-polar extractives
AU7592998A (en) Modulators of tissue regeneration
AU7043298A (en) Preparation of low-dust stabilisers
AU3963397A (en) Preparation of y zeolite
AU4944297A (en) Modulation of apoptosis
AU5237296A (en) Use of pyrrole compounds as antifouling agents
AU4261197A (en) Human protein kinases
AU5487298A (en) Novel therapeutic application of pyrrole derivatives
AU7450898A (en) Indole compounds
AU6620596A (en) Use of transglutaminase modulators to promote wound healing
AU2172899A (en) Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels
AU1044799A (en) Pharmaceutical composition containing zafirlukast